These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 37860991

  • 1. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
    Imakiire A, Morimoto H, Suzuki H, Masuda T, Yoden E, Inoue A, Morioka H, Konaka T, Mori A, Shirasaka R, Kato R, Hirato T, Sonoda H, Minami K.
    Mol Pharm; 2023 Nov 06; 20(11):5901-5909. PubMed ID: 37860991
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO® I.V. Infusion 10 mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)].
    Yamamoto R, Kawashima S.
    Nihon Yakurigaku Zasshi; 2022 Nov 06; 157(1):62-75. PubMed ID: 34980815
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A, Meisner R, Thomsen ER, Nguyen HN, Ravi R, Simms J, Lo I, Speckart J, Holtzman J, Gill TM, Chan D, Cheng Y, Chiu CL, Dugas JC, Fang M, Lopez IA, Solanoy H, Tsogtbaatar B, Zhu Y, Bhalla A, Henne KR, Henry AG, Delucchi A, Costanzo S, Harris JM, Diaz D, Scearce-Levie K, Sanchez PE.
    JCI Insight; 2021 Oct 08; 6(19):. PubMed ID: 34622797
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K, Mizoguchi A, Tachibana K, Hirato T, Takahashi K.
    Mol Ther; 2018 May 02; 26(5):1366-1374. PubMed ID: 29606503
    [Abstract] [Full Text] [Related]

  • 14. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y, Wakabayashi T, Akiyama K, Hoshina H, Higuchi T, Kobayashi H, Eto Y, Ida H, Ohashi T.
    Mol Genet Metab; 2016 Feb 02; 117(2):140-3. PubMed ID: 26051019
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, Kobayashi H, Ida H, Ohashi T, Morimoto H, Hirato T, Nishino K, Eto Y.
    Mol Genet Metab; 2012 Sep 02; 107(1-2):122-8. PubMed ID: 22704483
    [Abstract] [Full Text] [Related]

  • 16. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
    Mashima R, Ohira M, Okuyama T, Onodera M, Takada S.
    Sci Rep; 2023 May 15; 13(1):7865. PubMed ID: 37188686
    [Abstract] [Full Text] [Related]

  • 17. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR, Chaudrhy A, Ellison S, Searle R, Burgod C, Tehseen G, Forte G, O'Leary C, Gleitz H, Liao A, Cook J, Holley R, Bigger BW.
    Hum Gene Ther; 2024 Apr 15; 35(7-8):232-242. PubMed ID: 37212263
    [Abstract] [Full Text] [Related]

  • 18. Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
    Morimoto H, Morioka H, Imakiire A, Yamamoto R, Hirato T, Sonoda H, Minami K.
    Mol Ther Methods Clin Dev; 2022 Jun 09; 25():534-544. PubMed ID: 35662814
    [Abstract] [Full Text] [Related]

  • 19. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.
    Hoshina H, Shimada Y, Higuchi T, Kobayashi H, Ida H, Ohashi T.
    Mol Genet Metab; 2018 Feb 09; 123(2):118-122. PubMed ID: 29289480
    [Abstract] [Full Text] [Related]

  • 20. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K, Podetz-Pedersen KM, Nguyen TT, Evenstar LB, Kitto KF, Nan Z, Fairbanks CA, Low WC, Kozarsky KF, McIvor RS.
    Hum Gene Ther; 2017 Aug 09; 28(8):626-638. PubMed ID: 28478695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.